SOPHIA GENETICS SF -,05

SOPHiA GENETICS reported a 27% revenue increase to $23.3m in Q2, beating consensus, while the EPS loss of $0.30 was larger than expected. The platform recorded a record analysis volume of 115,000 tests (+22%) and saw stronger demand particularly in the US. Management raised the full-year revenue guidance to $94–96m, but confirmed the adjusted EBITDA loss guidance of $29–32m and expects adjusted EBITDA breakeven by the end of 2026; cash holdings rose to $107.7m following a capital measure. » Plus sur de.investing.com

SOPHiA GENETICS and AstraZeneca have agreed on a multi-year collaboration to develop and deploy two companion diagnostics for precision oncology therapies. SOPHiA GENETICS will advance its solution for solid tumors into a decentralized companion diagnostic and validate an application for hematologic oncology to support patients with blood cancers. The aim is to enable standardized tests across different geographical locations and to improve clinical decision-making through biomarker detection. » Plus sur de.investing.com

SOPHiA GENETICS completed a guaranteed public offering with gross proceeds of $57.5 million, selling 12,104,900 common shares at $4.75 each. The underwriting banks fully exercised a 1,578,900‑share overallotment option; the offering was oversubscribed and all shares were placed. The stock trades near its 52‑week high; the company recorded $81.18 million in revenue over the past twelve months with roughly 21% growth, but remains unprofitable. » Plus sur de.investing.com